The U.S. Food and Drug Administration (FDA) approved Foundayo, a new weight-loss pill developed by Eli Lilly, on April 1. The medication, which contains the active ingredient orforglipron, is designed for adults with obesity, overweight conditions, or weight-related health issues. Unlike many existing GLP-1 drugs, Foundayo can be taken at any time of day without food or water restrictions, offering greater flexibility for users.
Core Facts & Developments
- FDA Approval: Foundayo is the first oral GLP-1 drug approved for weight loss that can be taken without dietary restrictions.
- Clinical Results: In trials, participants lost an average of 15 to 20 pounds on higher doses, outperforming Novo Nordisk’s Rybelsus (8–11 pounds) in weight loss and A1C reduction.
Deeper Dive & Context
Comparison to Competitors
Foundayo competes with other GLP-1 drugs like Wegovy (Novo Nordisk) and Zepbound (Eli Lilly). While Wegovy’s oral version requires morning administration on an empty stomach, Foundayo can be taken at any time. Novo Nordisk claims Wegovy’s pill shows greater weight loss in indirect comparisons, but Lilly’s trials suggest Foundayo’s flexibility may appeal to more users.
Market Implications
The introduction of oral GLP-1 drugs is expected to expand the weight-loss medication market, as pills are easier to distribute and administer than injections. Eli Lilly’s CEO, Dave Ricks, emphasized Foundayo’s accessibility, while Novo Nordisk highlighted Wegovy’s efficacy in patient preference studies.
Broader Applications
Foundayo is also being studied for potential use in treating type 2 diabetes, obstructive sleep apnea, osteoarthritis, and other conditions. Clinical trials are ongoing to assess its effectiveness beyond weight loss.
Expert Perspectives
Deborah Horn, director of the Center for Obesity Medicine at UTHealth Houston, noted that fewer than 1 in 10 eligible patients currently use GLP-1 drugs. She emphasized the need for flexible treatment options to improve accessibility.
Availability
Foundayo will be available for shipment starting April 6, marking Eli Lilly’s second FDA-approved obesity medication alongside Zepbound.